KDMN - Kadmon Holdings: Pick Up This Late-Stage Biopharmaceutical Company In March 2020
Today, we will see why Kadmon Holdings (KDMN) is an attractive pick in March 2020.
Company overview
Founded in 2009, Kadmon Holdings went public in 2016. The company is a late-stage biopharmaceutical company focused on the development and commercialization of small molecule therapies and biologics in areas of immune and fibrotic diseases as well as immune-oncology. The company is currently studying small molecule ROCK2 inhibitor, KD025, in cGVHD (chronic graft-versus-host disease) indication after at least 2 prior lines of systemic therapy, in an ongoing pivotal trial. The company is also studying its lead